Gene editing startup Locus Biosciences is another step closer to actualizing its biotherapeutics against bacterial diseases after landing $35 million in additional capital.
Read More
Locus Biosciences, which is managing partnerships worth more than $1 billion, announced this morning it had closed a Series B fundraising round.
Read More
Locus Biosciences has raised more than $10.5 million in equity from three investors, according to an SEC filing, and the company could some $9 million more.
Read More
WRAL TechWire spoke with the cofounder and CEO of Locus Biosciences, Paul Garofolo, about the company’s expansion and location in the Research Triangle Park, and about the current state of the life science and biopharmaceutical industries.
Read More
Morrisville-based Locus Biosciences has entered a credit facility with Hercules Capital, Inc. of up to $25 million to expand the clinical-stage biotechnology company’s drug discovery platform and in-house manufacturing. Here’s what the company has planned.
Read More
Locus Biosciences has entered an agreement that could result in up to $25 million in financing, the company announced today.
Read More
RTP-based Locus Biosciences has completed its first-of-its-kind clinical trial of its CRISPR enhanced bacteriophage technology. The new approach to antibiotics has the potential to combat even germs that have developed multiple drug resistance to conventional antibiotics.
Read More
Locus Biosciences has inked nearly $1 billion in deals to develop its gene-editing and bacteriophage technology that could combat antibiotic resistance and which targets specific bad bacteria, leaving good bacteria unharmed. Here’s the story, exclusively for TechWire readers.
Read More
Gene editing startup Locus Biosciences has landed another $7 million in new cash, adding to a year that has brought commitments of nearly $100 million.
Read More
